News

Researchers developed a novel “closed-loop” system that delivered electrical pulses in a brain region to synchronize brain activity recorded from another region in the brain to improve memory.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 8, 2023.

The associate professor of psychiatry at the University of Illinois at Chicago talked about the importance of diverse insight and perspectives from the headache community in shaping medical research priorities. [WATCH TIME: 3 minutes]

Antinuclear antibodies seem to be more associated with severe disease activity and poor prognosis among patients with NMOSD, which further implies that they may be potentially used as a prognostic marker for the disease.

The associate professor at Yeshiva University and Albert Einstein College of Medicine explored the challenge of discussing lifestyle changes for patients with migraine, noting that lifestyle modifications can be a valuable addition to migraine treatment. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Beck, PhD. [LISTEN TIME: 15 minutes]

Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy.

Half of the treated individuals saw a reduction of more than 50% in the number and duration of epileptic spasms following treatment with CER-0001, a ketogenic therapy.

The president of the ANA and the chair of the annual meeting programming committee provided commentary on the advances in neurology and the shift in how clinicians approach and treat diseases once thought to be fatal. [WATCH TIME: 6 minutes]

Findings showed that autonomic symptom burden was slightly more severe in patients with multiple sclerosis compared with those with NMOSD, although the difference was not statistically significant.

Catch up on any of the neurology news headlines you may have missed over the course of August 2023, compiled all into one place by the NeurologyLive® team.

The president of the ANA and the chair of the annual meeting programming committee gave an overview on the various topics and courses the clinical community should home in on at the upcoming annual meeting. [WATCH TIME: 6 minutes]

The agency requested modifications to the REMS program, seeking validation of patients’ meningococcal vaccination status and prophylactic administration of antibodies prior to giving ravulizumab treatment.

Preliminarily data from in vitro experiments demonstrated that cytomegalovirus antigenic peptides can activate peripheral antigen-specific T cells among patients with NMOSD.

The headache specialist at Hartford Healthcare Headache Center emphasized the importance of avoiding unnecessary fear surrounding the potential link between migraine and dementia, as current evidence does not strongly support it being a significant risk factor. [WATCH TIME: 2 minutes]

The director of the ALS Clinic at Allegheny Health Network provided perspective on the advancements in the treatment and management of adult-onset spinal muscular atrophy.

An expert panel discusses diagnosis and treatment of patients with Parkinson disease, exploring the challenges in managing dyskinesia, finding a balance between OFF episodes and ON time, and current and emerging treatment options.

Nicolaas Bohnen, MD, PhD, professor of radiology and neurology at the University of Michigan, discussed the main takeaways from his keynote lecture on posture and gait in Parkinson disease presented at the 2023 MDS Congress.

The president of the ANA and the chair of the annual meeting programming committee provided perspective on the upcoming ANA Annual Meeting and what clinicians may get out of the meeting. [WATCH TIME: 7 minutes]

More than a 40% improvement in ON time without troublesome dyskinesia occurred as patients had their treatment titrated.

The chief medical officer at Avidity Biosciences talked about how its exon skipping AOC therapies are designed to address the lack of functional dystrophin protein among patients with Duchenne muscular dystrophy to improve muscle function. [WATCH TIME: 4 minutes]

On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.

The director of epilepsy surgery at Allegheny Health Network provided insight on the early discussions between patients with drug resistant epilepsy and clinicians seeking to find beneficial treatment strategies. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about striving to understand and address the disparities among Latinx patients with multiple sclerosis. [WATCH TIME: 2 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Findings from an open-label extension trial among 45 patients with ALS showed a significant median survival benefit of 19.3 months and a significant 52% decreased risk of ALS clinical worsening events after treatment.

A group of esteemed panelists discussed the important values neurology department directors and educators should prioritize when teaching students of the future. [WATCH TIME: 6 minutes]